Adamas Pharma (ADMS) Lower on $50M Stock Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharma (NASDAQ: ADMS) is lower after the company filed a prospectus covering $50 million in common stock. Shares will be offered through Cowen.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zai Lab raises $250M in PIPE financing for ADC drug development
- Increasing unusual put option volume: BUG BORR APO SECZ DB EWZ
- TransAlta sells 49% Oklahoma wind stake for US$305M, buys Colorado gas assets
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
